157 related articles for article (PubMed ID: 19476621)
1. Progesterone receptor does not improve the performance and test effectiveness of the conventional 3-marker panel, consisting of estrogen receptor, vimentin and carcinoembryonic antigen in distinguishing between primary endocervical and endometrial adenocarcinomas in a tissue microarray extension study.
Liao CL; Lee MY; Tyan YS; Kok LF; Wu TS; Koo CL; Wang PH; Chao KC; Han CP
J Transl Med; 2009 May; 7():37. PubMed ID: 19476621
[TBL] [Abstract][Full Text] [Related]
2. Ancillary p16(INK4a) adds no meaningful value to the performance of ER/PR/Vim/CEA panel in distinguishing between primary endocervical and endometrial adenocarcinomas in a tissue microarray study.
Yao CC; Kok LF; Lee MY; Wang PH; Wu TS; Tyan YS; Cheng YW; Kung MF; Han CP
Arch Gynecol Obstet; 2009 Sep; 280(3):405-13. PubMed ID: 19153755
[TBL] [Abstract][Full Text] [Related]
3. Adding the p16(INK4a) marker to the traditional 3-marker (ER/Vim/CEA) panel engenders no supplemental benefit in distinguishing between primary endocervical and endometrial adenocarcinomas in a tissue microarray study.
Han CP; Lee MY; Kok LF; Ruan A; Wu TS; Cheng YW; Tyan YS; Lin CY
Int J Gynecol Pathol; 2009 Sep; 28(5):489-96. PubMed ID: 19696622
[TBL] [Abstract][Full Text] [Related]
4. p16 INK4 and CEA can be mutually exchanged with confidence between both relevant three-marker panels (ER/Vim/CEA and ER/Vim/p16 INK4) in distinguishing primary endometrial adenocarcinomas from endocervical adenocarcinomas in a tissue microarray study.
Han CP; Lee MY; Tyan YS; Kok LF; Yao CC; Wang PH; Hsu JD; Tseng SW
Virchows Arch; 2009 Oct; 455(4):353-61. PubMed ID: 19763614
[TBL] [Abstract][Full Text] [Related]
5. A reappraisal of three-marker (ER/Vim/CEA), four-marker (ER/Vim/CEA/PR), and five-marker (ER/Vim/CEA/PR/p16INK4a) panels in the diagnostic distinction between primary endocervical and endometrial adenocarcinomas in a tissue microarray study.
Han CP; Lee MY; Kok LF; Wu TS; Cheng YW; Wang PH; Yue CH; Tyan YS
Arch Gynecol Obstet; 2010 May; 281(5):845-50. PubMed ID: 19847454
[TBL] [Abstract][Full Text] [Related]
6. Distinguishing between primary endocervical and endometrial adenocarcinomas: is a 2-marker (Vim/CEA) panel enough?
Liao CL; Hsu JD; Lee MY; Kok LF; Li YJ; Wang PH; Yao CC; Han CP
Virchows Arch; 2010 Apr; 456(4):377-86. PubMed ID: 20221633
[TBL] [Abstract][Full Text] [Related]
7. ProExC is a novel marker for distinguishing between primary endometrial and endocervical adenocarcinomas.
Esheba GE
J Egypt Natl Canc Inst; 2013 Jun; 25(2):87-93. PubMed ID: 23719407
[TBL] [Abstract][Full Text] [Related]
8. [Value of ER, VIM, CEA and p16 detection in the diagnosis and differential diagnosis of primary endocervical and endometrial adenocarcinomas].
Hu WW; Tao JH; Li GM; Xu X; Yang XM
Nan Fang Yi Ke Da Xue Xue Bao; 2010 Mar; 30(3):526-8, 531. PubMed ID: 20335127
[TBL] [Abstract][Full Text] [Related]
9. Five commonly used markers (p53, TTF1, CK7, CK20, and CK34betaE12) are of no use in distinguishing between primary endocervical and endometrial adenocarcinomas in a tissue microarray extension study.
Han CP; Kok LF; Lee MY; Wu TS; Ruan A; Cheng YW; Wang PH; Koo CL; Tyan YS
Arch Gynecol Obstet; 2010 Feb; 281(2):317-23. PubMed ID: 19444461
[TBL] [Abstract][Full Text] [Related]
10. Immunohistochemical staining in the distinction between primary endometrial and endocervical adenocarcinomas: another viewpoint.
Kamoi S; AlJuboury MI; Akin MR; Silverberg SG
Int J Gynecol Pathol; 2002 Jul; 21(3):217-23. PubMed ID: 12068166
[TBL] [Abstract][Full Text] [Related]
11. A panel of immunohistochemical stains, including carcinoembryonic antigen, vimentin, and estrogen receptor, aids the distinction between primary endometrial and endocervical adenocarcinomas.
McCluggage WG; Sumathi VP; McBride HA; Patterson A
Int J Gynecol Pathol; 2002 Jan; 21(1):11-5. PubMed ID: 11781517
[TBL] [Abstract][Full Text] [Related]
12. Immunoprofile of cervical and endometrial adenocarcinomas using a tissue microarray.
Alkushi A; Irving J; Hsu F; Dupuis B; Liu CL; Rijn M; Gilks CB
Virchows Arch; 2003 Mar; 442(3):271-7. PubMed ID: 12647218
[TBL] [Abstract][Full Text] [Related]
13. Distinction between endometrial and endocervical adenocarcinoma: an immunohistochemical study.
Castrillon DH; Lee KR; Nucci MR
Int J Gynecol Pathol; 2002 Jan; 21(1):4-10. PubMed ID: 11781516
[TBL] [Abstract][Full Text] [Related]
14. A panel of 3 markers including p16, ProExC, or HPV ISH is optimal for distinguishing between primary endometrial and endocervical adenocarcinomas.
Kong CS; Beck AH; Longacre TA
Am J Surg Pathol; 2010 Jul; 34(7):915-26. PubMed ID: 20534993
[TBL] [Abstract][Full Text] [Related]
15. Scoring mechanisms of p16INK4a immunohistochemistry based on either independent nucleic stain or mixed cytoplasmic with nucleic expression can significantly signal to distinguish between endocervical and endometrial adenocarcinomas in a tissue microarray study.
Koo CL; Kok LF; Lee MY; Wu TS; Cheng YW; Hsu JD; Ruan A; Chao KC; Han CP
J Transl Med; 2009 Apr; 7():25. PubMed ID: 19366452
[TBL] [Abstract][Full Text] [Related]
16. Scoring of p16(INK4a) immunohistochemistry based on independent nuclear staining alone can sufficiently distinguish between endocervical and endometrial adenocarcinomas in a tissue microarray study.
Han CP; Kok LF; Wang PH; Wu TS; Tyan YS; Cheng YW; Lee MY; Yang SF
Mod Pathol; 2009 Jun; 22(6):797-806. PubMed ID: 19347018
[TBL] [Abstract][Full Text] [Related]
17. Differential Diagnosis between Primary Endocervical and Endometrial Adenocarcinoma using Immunohistochemical Staining of Estrogen Receptor, Vimentin, Carcinoembryonic Antigen and p16.
Yanaranop M; Ayuwat S; Nakrangsee S
J Med Assoc Thai; 2016 Feb; 99 Suppl 2():S106-15. PubMed ID: 27266224
[TBL] [Abstract][Full Text] [Related]
18. Detection of high-risk human papillomavirus DNA and immunohistochemical expressions of p16, vimentin, ER, and PR in primary endocervical and endometrial adenocarcinomas.
Xiong Y; Xiong YY; Xu ZG
Eur J Gynaecol Oncol; 2016 Aug; 37(4):517-521. PubMed ID: 29894077
[TBL] [Abstract][Full Text] [Related]
19. True cytokeratin 8/18 immunohistochemistry is of no use in distinguishing between primary endocervical and endometrial adenocarcinomas in a tissue microarray study.
Hsu JD; Yao CC; Lee MY; Kok LF; Wang PH; Tyan YS; Han CP
Int J Gynecol Pathol; 2010 May; 29(3):282-9. PubMed ID: 20407331
[TBL] [Abstract][Full Text] [Related]
20. Immunohistochemistry and HPV in situ hybridization in pathologic distinction between endocervical and endometrial adenocarcinoma: a comparative tissue microarray study of 76 tumors.
Jones MW; Onisko A; Dabbs DJ; Elishaev E; Chiosea S; Bhargava R
Int J Gynecol Cancer; 2013 Feb; 23(2):380-4. PubMed ID: 23318908
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
